BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
금요일, 9월 18

Arcturus Therapeutics Holdings Inc

ARCTNASDAQ
Trade with Public
Trade with Public
$16.80
-0.13-0.77%
마지막 업데이트: Sep 18, 9:28 AM
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Arcturus Therapeutics Financials

Arcturus Therapeutics (ARCT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Arcturus Therapeutics Q2 EPS $(0.84) Beats $(1.00) Estimate, Sales $2.959M Miss $3.199M Estimate

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.00) by 16 percent. This is a 147.06 percent decrease over losses of $(0.34) per share
Benzinga Newsdesk

PRO
Arcturus Therapeutics Q1 EPS $(0.95) Beats $(1.00) Estimate, Sales $2.061M Miss $7.233M Estimate

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.00) by 5 percent. This is a 82.69 percent decrease over losses of $(0.52) per share from
Benzinga Newsdesk

Arcturus Therapeutics Q4 Earnings Assessment

Benzinga Insights

PRO
Arcturus Therapeutics Q4 EPS $(1.03) Misses $(0.98) Estimate, Sales $7.196M Miss $17.669M Estimate

Benzinga Newsdesk

Earnings Scheduled For March 3, 2026

Benzinga Insights

Earnings Preview: Arcturus Therapeutics

Benzinga Insights

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved